ArticleOpen access rheumatology : research and reviews2026
Care Gaps in Gout Management Within a Tertiary Academic Health System in Saudi Arabia: Implications for Quality Improvement.
Article in Open access rheumatology : research and reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gout is a common, treatable inflammatory arthritis, yet adherence to guideline-based care remains suboptimal worldwide. Data from Saudi Arabia evaluating real-world gout care processes are limited. Methods: We conducted a retrospective cohort study of adults with a a physician-documented diagnosis of gout who newly initiated allopurinol within a tertiary academic health system in Riyadh, Saudi Arabia, from January 2022 through December 2024. Pharmacy records were used to identify eligible patients, and electronic medical records were reviewed to extract demographic, clinical, and treatment data. Adherence to American College of Rheumatology (ACR) 2020 guideline-derived quality indicators was assessed, including guideline-concordant initiation of urate-lowering therapy (ULT), serum uric acid (SUA) monitoring, achievement of SUA <6 mg/dL, and use of anti-inflammatory prophylaxis. Multivariable logistic regression was used to identify predictors of adherence. Results: Among 120 patients, 35.8% met ACR 2020 criteria for ULT initiation. SUA was measured within 6 months of initiation in 41.7% of patients, and at least annually in 61.7% of patients with at least 12 months of follow-up. Among 115 patients with at least 12 months of follow-up and at least one documented SUA measurement, 32.2% achieved SUA <6 mg/dL. Anti-inflammatory prophylaxis was received at ULT initiation by 15 out of 107 eligible patients (14%). Primary care management was independently associated with lower odds of meeting initiation criteria (OR 0.05, 95% CI 0.01-0.16) and of achieving the target SUA (OR 0.23, 95% CI 0.06-0.89) compared with rheumatology. Older age (OR 0.97, 95% CI 0.92-1.00) and male sex (OR 0.29, 95% CI 0.10-0.83) were also associated with lower SUA target attainment. Conclusion: In this tertiary academic health system, guideline-recommended gout care processes were inconsistently executed across initiation, monitoring, target assessment, and prophylaxis domains. Primary care management was associated with lower odds of appropriate ULT initiation and target SUA attainment, and older age and male sex were also associated with lower target achievement. Standardized treat-to-target pathways supported by pharmacist- or nurse-led titration may improve performance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.